Hoth Therapeutics, Inc.

Analysis for Ticker: HOTH

Hoth Therapeutics Inc develops treatments for conditions like cancer toxicities, Alzheimer disease, and obesity, but it functions as a mechanism to transform public investment into executive compensation. By 01/2026, the company had accumulated a deficit of 72,9$ million without ever generating revenue from a single product sale. This is a business where the math of survival is a terminal spiral. Imagine a company that pays its leaders millions of dollars to manage science experiments that never make money. To pay these leaders, the company prints new shares of stock, which acts like adding more water to a soup until the flavor disappears for everyone who already owns a bowl. The cycle of extraction began clearly in 01/2025. In 06/2025, the company gave 300.000 warrants worth 333.150$ to a consultant just to help them promote the stock to more people. During the third quarter of that year, the chief executive officer Robb Knie was handed 800.000 shares worth 968.000$ while the company lost 9,78$ million in nine months. Management even used 300.000$ of their remaining cash to buy digital tokens like Bitcoin and Ethereum and immediately lost 25.305$ on the gamble. By 09/2025, the company used a temporary stock price peak of 2,07$ to justify selling more shares even though the actual price was already falling. On 17/10/2025, the chief executive filed a public document containing no financial math, just generic presentation slides to control the narrative.